Intranasal Antiviral Immune Enhancers

Boosting local host defence to stop respiratory viral infections in their tracks

ENA Respiratory is a clinical-stage pharmaceutical company. We are tackling symptomatic infections and resulting serious complications (sequelae) of respiratory viral infections through the development of first-in-class, small molecule prophylactics, which locally prime and boost the body’s natural first line of defence.

The company’s host defense enhancers have been shown in preclinical and clinical studies to be effective against a diverse range of respiratory viruses, including SARS-CoV2, rhinovirus, H1N1, and seasonal influenza strains.

INNA-051

A first-in-class prophylaxis

The company’s antiviral host defense enhancers have been shown in preclinical and clinical studies to be effective against a diverse range of common respiratory viruses, including SARS-CoV-2, rhinovirus, H1N1, and seasonal influenza strains.

It offers solutions to protect against common and emerging respiratory viruses for which vaccines or direct-acting antivirals have limitations or do not exist.

INNA-051 is being developed as a convenient, once-a-week nasal dry powder product for self-administration.

Learn more

Clinical Studies

Advancing INNA-051 into Phase 2 studies

Previous clinical studies have demonstrated a favourable safety profile for INNA-051, supporting seasonal prophylaxis use. In a phase 2a proof-of-principle study using a human influenza-challenge model, INNA-051 enabled accelerated virus clearance and stimulation of antiviral host defences, including Interferon (IFN) Type I & III responses.

Treating vulnerable patients and at-risk populations

INNA-051 addresses a significant medical and market need; the burden of serious viral respiratory infections in at risk populations.

This includes the elderly, those with an underlying medical condition such as chronic lung conditions, diabetes, kidney disease, and cardiovascular disease, and individuals with occupational risk e.g. first responders, military or essential services personnel.

Our Investors

The company has raised financing from Brandon Capital, The Minderoo Foundation, Uniseed and Flu Lab.

Our Partnerships

JPEO-CBRND

ENA Respiratory has been awarded a contract from the U.S. Government’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) to support the ongoing development of INNA-051 as part of its pandemic preparedness program.

Vew press release

COPD Foundation

In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators.

Vew press release

Blue Knight

ENA Respiratory is an alumni member of BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and U.S. BARDA (Biomedical Advanced Research and Development Authority) designed to accelerate novel potential solutions for future pandemics.

Vew press release

Intranasal Antiviral Immune Enhancers

Boosting local host defence to stop respiratory viral infections in their tracks

INNA-051

A first-in-class prophylaxis

Clinical Studies

Advancing INNA-051 into Phase 2 studies

Treating vulnerable patients and at-risk populations

INNA-051 addresses a significant medical and market need; the burden of serious viral respiratory infections in at risk populations.

Our Investors

The company has raised financing from Brandon Capital, The Minderoo Foundation, Uniseed and Flu Lab.

Our Partnerships

JPEO-CBRND

COPD Foundation

Blue Knight

Location

ENA Respiratory is headquartered in Melbourne, Australia, with operations in the USA.